The bidding for MedImmune Inc. can now begin in earnest. The Gaithersburg, Md.-based company, apparently bowing to pressure from disgruntled shareholders, said it was exploring the option of selling the company. Opening bids likely would start at more than $10 billion, following the 15.3 percent gain in the stock's price Thursday. (BioWorld Today)